Alphabet's Isomorphic Labs raises $5 billion to push AI-designed drugs toward trials
Isomorphic Labs, the AI drug discovery company led by Demis Hassabis, raised $5 billion just six months after a $2.1 billion round. It plans to move its drug pipeline toward clinical trials, though it has no approved drugs yet.
Why it matters
Investors are betting heavily that AI can speed up drug discovery, but the real test will be results in human trials.
aii.news picks and summarizes stories from trusted news sources with the help of AI. Every story links to the original reporting. How we work.